Linezolid toxicity in clinical practice: towards a better detection of at-risk patients? Interim analysis of a prospective multicentric study

Thirot, Hélène;Fage, David;Yombi, Jean Cyr;Cornu, Olivier;Van Bambeke, Françoise;et.al.
(2023) 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) — Location: (Denmark) Copenhagen (15.April.2023)

Files

2023_Thirion_ECCMID_01839.pdf
  • Open Access
  • Adobe PDF
  • 230.6 KB
Download

Details

Authors
Show more
Abstract
Background : In a retrospective study in 4 Belgian hospitals, we showed that the use of linezolid (LZD) was larger and the rate of adverse drug reactions (ADRs) higher (especially anemia and thrombocytopenia) than described in the summary of product characteristics (1). Associated risk factors for ADRs were long treatment duration, renal impairment at the treatment initiation, and presence of comorbidities (evaluated by the Charlson index (2)). Moreover, literature suggests that trough levels (Cmin) > 9 mg/L increase the risk of hematological toxicity (HT) [...].
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Thirot, H., Fage, D., Yombi, J. C., Cornu, O., Briquet, C., Clevenbergh, P., Besse, T., Cotton, F., Spinewine, A., & Van Bambeke, F. (2023). Linezolid toxicity in clinical practice: towards a better detection of at-risk patients? Interim analysis of a prospective multicentric study. 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), (Denmark) Copenhagen. https://hdl.handle.net/2078.5/101779